A multi-center, double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of 14-day inhaled TPI ASM8 in subjects with asthma.

Trial Profile

A multi-center, double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of 14-day inhaled TPI ASM8 in subjects with asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2012

At a glance

  • Drugs ASM 8 (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 14 Dec 2008 Trial end date changed from 1 Jul 2008 to 1 Oct 2008 as reported by Clinicaltrials.gov.
    • 14 Dec 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top